Boehringer Ingelheim
For Healthcare Professionals

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

12/04/2024  |  Author: Boehringer Ingelheim

Document ID: RD-123384

Sequencing

Sequential treatment afatinib
RWDRI||Real-World Effectiveness of Sequential GIOTRIF® & osimertinib - Data from GIOTAG and RESET studies
SEREAL||GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)
Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC (CNS cohort)
GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
MYSEREAL||GIOTRIF® followed by 3rd generation TKI in RESET study
SEREAL||Japan real world evidence supports sequential treatment with the use of upfront 2nd generation TKI
SEREAL||GioTag, the 1st global study to show feasibility of sequential therapy with GIOTRIF® followed by osimertinib
SEREAL||Post-hoc analyses from LUX-Lung trials: GIOTRIF(R) followed by 3rd generation TKI
SEREAL||Uptake of subsequent therapy in LUX-Lung 3, 6 and 7
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study
Totality Outcome of Afatinib (GIOTRIF®) Sequential Treatment in Patients with EGFRM+ NSCLC

RELATED CONTENT